Delivery Order SPE2DB22D2006-SPE2DB25FW1BW

Award Date 5/21/25
Potential Completion Date 5/22/25
Potential Value $50K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication. The contract has a ceiling value of $1,117.80 and a performance period extending through May 8, 2025. It is a firm fixed-price contract, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication, with a ceiling value of $43,433.74 and a performance period through May 2, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription eye medication, with a ceiling value of $3,156.12 and a period of performance through February 14, 2025. This appears to be a firm fixed-price contract without any set-aside requirements, allowing for open competition. Amerisourcebergen...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $4,527.84 and an ultimate completion date of January 8, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract has a firm fixed price of $1,090.48 and a period of performance through May 12, 2025. The contract is not set aside and was awarded on May 9, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,160.96, is for the delivery of RESTASIS 0.05% eye emulsion, with a completion date of February 15, 2023. The contract is a firm fixed-price, delivery order type, and was not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a significant...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication, with a ceiling value of $17,658.44 and a performance period extending to June 16, 2025. The contract is designated as a Firm Fixed Price delivery order, with no set-aside used. Amerisourcebergen Drug Corp holds a...
This is a delivery order awarded to Amerisourcebergen Drug Corp by the Defense Logistics Agency (DLA) for the supply of RESTASIS 0.05% eye emulsion. The contract has a ceiling value of $12,425.52 and a performance period ending on July 23, 2024. The contract is a firm fixed-price arrangement and is not set aside for any specific business type. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, holding several Indefinite...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty medication, with a ceiling value of $2,749.32 and a completion date of July 20, 2022. The contract is an Indefinite Delivery Contract (IDC) valued at $999,999,999, which serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp's Corporate Office Division. The contract is for the supply of RESTASIS 0.05% Eye Emulsion 60s, a prescription pharmaceutical product, with a ceiling value of $3,126.34 and a completion date of May 24, 2024. AmerisourceBergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with the DLA valued up to $999,999,999.00...
  • SPE2DB22D2006
    Indefinite Delivery Contract
  • SPE2DB22D2006-SPE2DB25FW1BW
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, with a ceiling value of $49,706.46 and a period of performance through May 22, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers such as the Defense Health Agency and U.S. Coast Guard.

Generated 8/20/25, 9:53 AM